ELN 2021 future improvement of MRD recommendations based on a Delphi poll
| No. . | Future improvement of MRD recommendation . | LoE . | GoR . | LoA (%) . |
|---|---|---|---|---|
| C1 | LSCs can be immunophenotypically defined as CD34+/CD38− cells55 combined with an aberrant marker not present on HSCs (eg, CD45RA, CLL-1, or CD123). | IV | A | 95 |
| C2 | Measurements of LSCs may have prognostic value and should be further validated in prospective clinical trials. | IV | B | 86 |
| C3 | LSC detection requires optimally 4 million events, most likely best achieved with a 1-tube assay. | V | B | 78 |
| C4 | High-quality flow cytometry data (standardized instrument settings, preanalytics, and measurements) are necessary for future automated analyses. | IV | A | 100 |
| No. . | Future improvement of MRD recommendation . | LoE . | GoR . | LoA (%) . |
|---|---|---|---|---|
| C1 | LSCs can be immunophenotypically defined as CD34+/CD38− cells55 combined with an aberrant marker not present on HSCs (eg, CD45RA, CLL-1, or CD123). | IV | A | 95 |
| C2 | Measurements of LSCs may have prognostic value and should be further validated in prospective clinical trials. | IV | B | 86 |
| C3 | LSC detection requires optimally 4 million events, most likely best achieved with a 1-tube assay. | V | B | 78 |
| C4 | High-quality flow cytometry data (standardized instrument settings, preanalytics, and measurements) are necessary for future automated analyses. | IV | A | 100 |
GoR, grade of recommendation; LoA, level of agreement; LoE, level of evidence.